감염증 공동 연구 및 라이선싱 계약(2020-2026년)

Infectious Diseases Collaboration and Licensing Deals

Stop guessing. Start benchmarking real deals.

If you're working on an infectious disease deal, you don't need more opinions - you need evidence.

This report gives you direct access to 1,700+ real-world partnerships, so you can see exactly how deals are structured, valued, and negotiated across vaccines, antivirals, antibiotics, and emerging technologies.

Know what a "good deal" actually looks like

Without real benchmarks, you're negotiating in the dark.

With this report, you can:

• Anchor negotiations with real precedent
• See what companies are actually paying - not what they claim in press releases
• Benchmark deal terms instantly
• Compare upfronts, milestones, and royalty structures across relevant transactions
• Avoid overpaying or underselling
• Understand the realistic range for deals at your stage and in your space
• Challenge counterpart assumptions with data
• Walk into negotiations backed by hard evidence, not guesswork
• See how deals are really written - not just announced
• Most datasets stop at headlines. That's not enough.

This report gives you access to actual contracts, so you can see:

• How rights are allocated
• What partners commit to (and what they don't)
• How payments are structured and triggered
• Where risks and flexibilities sit
• This is the detail that defines deal outcomes - and it's usually hidden.
• Built for teams actively doing deals

Whether you're licensing, partnering, or evaluating opportunities, this report helps you:

• Move faster with immediate access to relevant comparables
• De-risk decisions using real transaction evidence
• Strengthen internal alignment with credible market data
• Negotiate from a position of strength
• What you get
• 1,700+ infectious disease deals
• Financial terms, including royalties where disclosed
• Fully searchable deal database (by company, therapy, technology, stage)
• Direct access to SEC-filed agreements
• 850+ pages of structured deal analysis
• The bottom line
• If you're making decisions on incomplete information, you're taking unnecessary risk.
• This report gives you the data, benchmarks, and contract-level insight to structure better deals - and win them.
• Request a sample or speak to us about how this can support your current deal work.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in infectious diseases dealmaking

• 2.1. Introduction
• 2.2. Infectious diseases partnering over the years
• 2.3. Infectious diseases partnering by deal type
• 2.4. Infectious diseases partnering by industry sector
• 2.5. Infectious diseases partnering by stage of development
• 2.6. Infectious diseases partnering by technology type
• 2.7. Infectious diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for infectious diseases partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for infectious diseases partnering
• 3.3. Infectious diseases partnering headline values
• 3.4. Infectious diseases deal upfront payments
• 3.5. Infectious diseases deal milestone payments
• 3.6. Infectious diseases royalty rates

Chapter 4 - Leading infectious diseases deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in infectious diseases partnering
• 4.3. List of most active dealmakers in infectious diseases
• 4.4. Top infectious diseases deals by value

Chapter 5 - Infectious diseases contract document directory

• 5.1. Introduction
• 5.2. Infectious diseases partnering deals where contract document available

Chapter 6 - Infectious diseases dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by infectious diseases therapeutic target
• Deal directory
• Deal directory - Infectious diseases deals by company A-Z
• Deal directory - Infectious diseases deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Infectious diseases partnering since 2020
• Figure 2: Infectious diseases partnering by deal type since 2020
• Figure 3: Infectious diseases partnering by industry sector since 2020
• Figure 4: Infectious diseases partnering by stage of development since 2020
• Figure 5: Infectious diseases partnering by technology type since 2020
• Figure 6: Infectious diseases partnering by indication since 2020
• Figure 7: Infectious diseases deals with a headline value
• Figure 8: Infectious diseases deals with upfront payment values
• Figure 9: Infectious diseases deals with milestone payment
• Figure 10: Infectious diseases deals with royalty rates
• Figure 11: Active infectious diseases dealmaking activity since 2020
• Figure 12: Top infectious diseases deals by value since 2020